Technetium Tc-99m arcitumomab

DB00113ExperimentalProtein Based Therapies

Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen (CEA) covalently labeled with Technitium 99. The molecule has a molecular weight...

Mechanism: Binds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors.
Curator reviewed
Primary indication: For imaging colorectal tumorsCurator reviewed
Formula / weight: C₆₃₉₈H₉₉₀₀N₁₇₁₄O₁₉₉₅S₅₄ · 144482.5 Da
Also known as: Arcitumomab technetium-99m · Technetium (99mTc) arcitumomab · Technetium Tc 99m arcitumomab · Technetium-99m arcitumomab

Resolves to

Compound

UNII029JF1SCU8CAS154361-49-6ChEMBLCHEMBL2108253

Clinical / RWD

RxNorm230435ATCV09IA06PharmGKBPA164746540

Targets

P06731CEACAM5P13688CEACAM1

What you can answer from here — as of July 17, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

1ATC codeIncluding every combination product, plus 12 drug categories

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Technetium Tc-99m arcitumomab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account